Human milk oligosaccharide

Global Human Milk Oligosaccharides Market Report to 2027 - Featuring Glycom, Elicityl, Medolac and BASF Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, November 25, 2022

Human milk oligosaccharides have several primary functions, including infection prevention, supply of sialic acid for brain development, and prebiotic effects.

Key Points: 
  • Human milk oligosaccharides have several primary functions, including infection prevention, supply of sialic acid for brain development, and prebiotic effects.
  • Infant formulas made from bovine milk have a lower concentration of oligosaccharides than human milk.
  • Several enzymes and chemicals used in the production of human milk oligosaccharides are extremely expensive and scarce.
  • The availability of new technologies such as enzymatic trans-glycosylation, which is used for artificially synthesizing HMOs, is one of the major factors and market trends that boosts the Human Milk Oligosaccharides (HMO) market growth.

World Human Milk Oligosaccharides Market Outlook and Opportunities Report 2021-2028: What's Next for Companies, Demand, Size, Strategies - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 7, 2022

The "2021 Human Milk Oligosaccharides Market Outlook and Opportunities in the Post Covid Recovery - What's Next for Companies, Demand, Human Milk Oligosaccharides Market Size, Strategies, and Countries to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2021 Human Milk Oligosaccharides Market Outlook and Opportunities in the Post Covid Recovery - What's Next for Companies, Demand, Human Milk Oligosaccharides Market Size, Strategies, and Countries to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The Human Milk Oligosaccharides market report analyses companies, market size outlook across types, applications, countries along with competitive strategies, trends, drivers, opportunities and market developments.
  • Human Milk Oligosaccharides Market Driving Factors, Restraints, and Opportunities
    The global Human Milk Oligosaccharides market has significant market potential and offers diverse opportunities across countries.
  • The report scope encompasses major Human Milk Oligosaccharides types and major Human Milk Oligosaccharides applications worldwide and presents a detailed analysis and outlook of each specific Human Milk Oligosaccharides type and application.

Human Milk Supplement Shown to Boost Immunological Activity

Retrieved on: 
Tuesday, September 14, 2021

The study evaluated the impact of Human Milk BionutrientsTM (HMBsTM) treatment in human-derived PBMC's against K562 cells, a commonly used immortalized leukemia cell line.

Key Points: 
  • The study evaluated the impact of Human Milk BionutrientsTM (HMBsTM) treatment in human-derived PBMC's against K562 cells, a commonly used immortalized leukemia cell line.
  • In these experiments, human milk bionutrients were added to PMBC's in the presence of K562 and treated for 48-hours.
  • Trulacta is composed entirely of thousands of beneficial components found in human milk, all of which are essential for health and wellbeing.
  • The company's flagship product Trulactais the world's first supplement for adults entirely composed of Human Milk Bionutrients (HMB's), the rich multitude of beneficial nutrients contained in human milk.

Inbiose applies for FDA GRAS approval of four new Human Milk Oligosaccharides

Retrieved on: 
Tuesday, July 6, 2021

Inbiose will also file for Novel Food approval of these HMOs by the European Commission (EFSA) in the coming weeks and is preparing a global regulatory roll-out.

Key Points: 
  • Inbiose will also file for Novel Food approval of these HMOs by the European Commission (EFSA) in the coming weeks and is preparing a global regulatory roll-out.
  • Inbiose has been developing a wide range of human-identical milk oligosaccharides that can be industrially produced by sustainable fermentation processes.
  • Inbiose is currently developing its next generation HMOs that will permit infant formula to better replicate the composition of breast milk.
  • Inbiose is a Belgium-based biotech company focused on the research, development and commercialization of specialty carbohydrates, including human milk oligosaccharides.

Inbiose applies for FDA GRAS approval of four new Human Milk Oligosaccharides

Retrieved on: 
Tuesday, July 6, 2021

Inbiose will also file for Novel Food approval of these HMOs by the European Commission (EFSA) in the coming weeks and is preparing a global regulatory roll-out.

Key Points: 
  • Inbiose will also file for Novel Food approval of these HMOs by the European Commission (EFSA) in the coming weeks and is preparing a global regulatory roll-out.
  • Inbiose has been developing a wide range of human-identical milk oligosaccharides that can be industrially produced by sustainable fermentation processes.
  • Inbiose is currently developing its next generation HMOs that will permit infant formula to better replicate the composition of breast milk.
  • Inbiose is a Belgium-based biotech company focused on the research, development and commercialization of specialty carbohydrates, including human milk oligosaccharides.

Global Human Milk Oligosaccharides (HMO) Markets, 2016-2019 & 2020-2026 - Rise in Health Awareness Among People and the Popularity of Artificial Synthesis Methods - ResearchAndMarkets.com

Retrieved on: 
Friday, January 8, 2021

HMOs (Human Milk Oligosaccharides) are sugars present in human breast milk and are the third-most-abundant solid component (after lactose and fats).

Key Points: 
  • HMOs (Human Milk Oligosaccharides) are sugars present in human breast milk and are the third-most-abundant solid component (after lactose and fats).
  • The growth of the Human Milk Oligosaccharides industry is accentuated by a variety of factors.
  • Human Milk Oligosaccharides (HMOs) have recently been used as an essential component of food supplements and infant formulas.
  • Infant formulas, developed from bovine milk, contain less concentration of oligosaccharides compared to human milk.

Kyowa Hakko Bio Establishes New Facility in Thailand to Supply Human Milk Oligosaccharides Worldwide

Retrieved on: 
Wednesday, November 4, 2020

TOKYO, Nov. 4, 2020 /PRNewswire-PRWeb/ --KYOWA HAKKO BIO CO. LTD. (Kyowa Hakko Bio), a subsidiary of Kirin Holdings Company, Limited (Kirin Holdings), has announced that it will establish a new facility to manufacture human milk oligosaccharides (HMOs) in Thailand.

Key Points: 
  • TOKYO, Nov. 4, 2020 /PRNewswire-PRWeb/ --KYOWA HAKKO BIO CO. LTD. (Kyowa Hakko Bio), a subsidiary of Kirin Holdings Company, Limited (Kirin Holdings), has announced that it will establish a new facility to manufacture human milk oligosaccharides (HMOs) in Thailand.
  • Kyowa Hakko Bio decided on the move with expectations of a future increase in global demand for HMOs.
  • The new facility is to be established at Kyowa Hakko Bio's subsidiary Thai Kyowa Biotechnologies Co., Ltd. (Thai Kyowa) in Rayong Province, Thailand.
  • Kyowa Hakko Bio will be able to secure a competitive advantage through its strain development and manufacturing process development capabilities.

DuPont Research Demonstrates Impact of Strain Specificity on Human Milk Oligosaccharide Utilization

Retrieved on: 
Monday, October 12, 2020

MADISON, Wis., Oct. 12, 2020 /PRNewswire-PRWeb/ -- Continuing its leading research on human milk oligosaccharides (HMOs), DuPont Nutrition & Biosciences released the findings of a new study demonstrating the importance of probiotic strain specificity, even within a sub-species, when related to efficient utilization of Human Milk Oligosaccharides (HMOs).

Key Points: 
  • MADISON, Wis., Oct. 12, 2020 /PRNewswire-PRWeb/ -- Continuing its leading research on human milk oligosaccharides (HMOs), DuPont Nutrition & Biosciences released the findings of a new study demonstrating the importance of probiotic strain specificity, even within a sub-species, when related to efficient utilization of Human Milk Oligosaccharides (HMOs).
  • Several species of Bifidobacterium have been shown to utilize HMOs, but little work has been done to study utilization variations within the species or sub-species.
  • "We are excited to further the research on defining the individual strain's role within the complex system of the microbiome.
  • DuPont, the DuPont Oval Logo, and all trademarks and service marks denoted with , SM or are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

Sugarlogix Welcomes Paula Hicks as new Chief Technology Officer

Retrieved on: 
Wednesday, September 30, 2020

OAKLAND, Calif., Sept. 30, 2020 /PRNewswire-PRWeb/ -- Sugarlogix , a bioengineering company creating functional oligosaccharides with health benefits, today announced the appointment of Paula Hicks as its new Chief Technology Officer (CTO).

Key Points: 
  • OAKLAND, Calif., Sept. 30, 2020 /PRNewswire-PRWeb/ -- Sugarlogix , a bioengineering company creating functional oligosaccharides with health benefits, today announced the appointment of Paula Hicks as its new Chief Technology Officer (CTO).
  • Before joining Sugarlogix, Hicks was at Evolva for more than seven years, most recently as the Senior Vice President of Technology in the Commercial Team.
  • While at Evolva, Hicks had vital leadership roles in commercializing products such as stevia, vanillin, and nootkatone.
  • "Sugarlogix's novel technology to utilizing yeast to produce HMOs (human milk oligosaccharides) and the technology's relative maturity immediately impressed me," said Hicks.

Conagen’s Novel Non-GMO Human Milk Oligosaccharide Paves the Way for Advancing Nutrition in Next Generation Infant Formulas

Retrieved on: 
Wednesday, August 19, 2020

This micronutrition breakthrough will enable the creation of high-quality and cost-effective next generation infant formula products that most closely resemble human breast milk.

Key Points: 
  • This micronutrition breakthrough will enable the creation of high-quality and cost-effective next generation infant formula products that most closely resemble human breast milk.
  • Human milk oligosaccharides are complex sugars that are naturally found in human milk.
  • They are the third largest solid component in human milk after fat and lactose, and convey a variety of benefits.
  • Conagens HMO product therefore offers source-sensitive consumers a pure, sustainable alternative ingredient for infant nutrition products.